JP2001508294A - 真核細胞遺伝子発現カセットおよびその使用 - Google Patents
真核細胞遺伝子発現カセットおよびその使用Info
- Publication number
- JP2001508294A JP2001508294A JP53066398A JP53066398A JP2001508294A JP 2001508294 A JP2001508294 A JP 2001508294A JP 53066398 A JP53066398 A JP 53066398A JP 53066398 A JP53066398 A JP 53066398A JP 2001508294 A JP2001508294 A JP 2001508294A
- Authority
- JP
- Japan
- Prior art keywords
- expression cassette
- promoter
- gene
- expression
- heterologous gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 150
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 166
- 241000700584 Simplexvirus Species 0.000 claims abstract description 60
- 239000013598 vector Substances 0.000 claims abstract description 40
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 14
- 230000007733 viral latency Effects 0.000 claims abstract 2
- 241000700605 Viruses Species 0.000 claims description 60
- 210000004027 cell Anatomy 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 16
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 16
- 230000006870 function Effects 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 15
- 229920001184 polypeptide Polymers 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 230000003612 virological effect Effects 0.000 claims description 11
- 210000003169 central nervous system Anatomy 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 210000001508 eye Anatomy 0.000 claims description 9
- 238000001415 gene therapy Methods 0.000 claims description 8
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000000651 prodrug Substances 0.000 claims description 7
- 229940002612 prodrug Drugs 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 210000004165 myocardium Anatomy 0.000 claims description 6
- 210000000653 nervous system Anatomy 0.000 claims description 6
- 210000002027 skeletal muscle Anatomy 0.000 claims description 6
- 231100000433 cytotoxic Toxicity 0.000 claims description 5
- 230000001472 cytotoxic effect Effects 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 208000020431 spinal cord injury Diseases 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 230000036210 malignancy Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 108091023040 Transcription factor Proteins 0.000 claims description 3
- 102000040945 Transcription factor Human genes 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 230000004962 physiological condition Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 230000031539 regulation of cell division Effects 0.000 claims 1
- 210000002363 skeletal muscle cell Anatomy 0.000 claims 1
- 230000007774 longterm Effects 0.000 abstract description 20
- 101710130522 mRNA export factor Proteins 0.000 description 28
- 101150066555 lacZ gene Proteins 0.000 description 19
- 241000701022 Cytomegalovirus Species 0.000 description 13
- 238000010186 staining Methods 0.000 description 13
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 12
- 241000713869 Moloney murine leukemia virus Species 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 9
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 8
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 239000005090 green fluorescent protein Substances 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 239000013603 viral vector Substances 0.000 description 8
- 108700039887 Essential Genes Proteins 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 239000013600 plasmid vector Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 description 5
- 101150027249 RL1 gene Proteins 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000000415 inactivating effect Effects 0.000 description 4
- 210000003594 spinal ganglia Anatomy 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 3
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 3
- 101150050057 UL43 gene Proteins 0.000 description 3
- 101150081415 UL55 gene Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 101150029683 gB gene Proteins 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000011694 lewis rat Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 210000001577 neostriatum Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 210000000063 presynaptic terminal Anatomy 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 3
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000005367 Carboxypeptidases Human genes 0.000 description 2
- 108010006303 Carboxypeptidases Proteins 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- 241000700589 Herpes simplex virus (type 1 / strain 17) Species 0.000 description 2
- 101100195053 Human herpesvirus 1 (strain 17) RIR1 gene Proteins 0.000 description 2
- 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 description 2
- 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 description 2
- 101150090364 ICP0 gene Proteins 0.000 description 2
- 101150027427 ICP4 gene Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 241001234870 P2virus Species 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000004330 Rhodopsin Human genes 0.000 description 2
- 108090000820 Rhodopsin Proteins 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012411 cloning technique Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- -1 for example Proteins 0.000 description 2
- 210000000609 ganglia Anatomy 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101800000342 Glycoprotein C Proteins 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000624947 Homo sapiens Nesprin-1 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 101150076998 ICP34.5 gene Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 101150062031 L gene Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 101710125058 Leucine aminopeptidase 2, chloroplastic Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- BNQSTAOJRULKNX-UHFFFAOYSA-N N-(6-acetamidohexyl)acetamide Chemical compound CC(=O)NCCCCCCNC(C)=O BNQSTAOJRULKNX-UHFFFAOYSA-N 0.000 description 1
- 102100023306 Nesprin-1 Human genes 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 102000004459 Nitroreductase Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 101150008375 Pou4f1 gene Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101000632473 Rattus norvegicus Pulmonary surfactant-associated protein D Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101100002024 Thermus aquaticus pstI gene Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 101150009795 UL54 gene Proteins 0.000 description 1
- 101150015312 UL56 gene Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108020001162 nitroreductase Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000009844 retrograde axon cargo transport Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000013363 skeletal muscle disease Diseases 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 101150046896 trm1 gene Proteins 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9700411.3 | 1997-01-10 | ||
| GBGB9700411.3A GB9700411D0 (en) | 1997-01-10 | 1997-01-10 | Eukaryotic gene expression cassette and uses thereof |
| PCT/GB1998/000074 WO1998030707A2 (en) | 1997-01-10 | 1998-01-12 | Eukaryotic gene expression cassette and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001508294A true JP2001508294A (ja) | 2001-06-26 |
| JP2001508294A5 JP2001508294A5 (enExample) | 2005-07-14 |
Family
ID=10805768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53066398A Ceased JP2001508294A (ja) | 1997-01-10 | 1998-01-12 | 真核細胞遺伝子発現カセットおよびその使用 |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP1021553B1 (enExample) |
| JP (1) | JP2001508294A (enExample) |
| KR (1) | KR100507399B1 (enExample) |
| CN (1) | CN1231589C (enExample) |
| AT (1) | ATE267263T1 (enExample) |
| AU (1) | AU749064B2 (enExample) |
| BR (1) | BR9806866A (enExample) |
| CA (1) | CA2278326A1 (enExample) |
| DE (1) | DE69824027T2 (enExample) |
| DK (1) | DK1021553T3 (enExample) |
| ES (1) | ES2221980T3 (enExample) |
| GB (1) | GB9700411D0 (enExample) |
| IL (2) | IL130876A0 (enExample) |
| PT (1) | PT1021553E (enExample) |
| WO (1) | WO1998030707A2 (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016525349A (ja) * | 2013-07-17 | 2016-08-25 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞 |
| US10172893B2 (en) | 2013-10-28 | 2019-01-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Oncolytic HSV vector |
| US10328136B2 (en) | 2010-04-16 | 2019-06-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors |
| US10391132B2 (en) | 2016-01-27 | 2019-08-27 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| JP2022534119A (ja) * | 2019-05-30 | 2022-07-27 | ソリッド・バイオサイエンシーズ・インコーポレーテッド | 組換えヘルペスウイルスベクター |
| US11612625B2 (en) | 2017-07-26 | 2023-03-28 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| GB9807865D0 (en) * | 1998-04-09 | 1998-06-10 | Univ London | Herpes simplex virus latency associated transcript polypeptides |
| US6713067B2 (en) | 1998-07-31 | 2004-03-30 | Biovex Limited | Herpes viruses for immune modulation |
| WO2000008193A2 (en) * | 1998-07-31 | 2000-02-17 | Cambridge University Technical Services Limited | Latency-active regulatory sequences of herpesviruses and latency-inactive herpesvirus for gene transfer |
| GB9930418D0 (en) | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
| US7063851B2 (en) | 2000-04-12 | 2006-06-20 | Biovex Limited | Herpes viruses for immune modulation |
| CZ2003798A3 (cs) | 2000-09-21 | 2003-08-13 | Dsm N. V. | Polypeptid s aktivitou xylanázy, sekvence nukleové kyseliny kódující polypeptid, způsob přípravy a použití polypeptidu |
| AUPR518501A0 (en) | 2001-05-22 | 2001-06-14 | Unisearch Limited | Yin yang-1 |
| TWI328612B (en) | 2002-07-25 | 2010-08-11 | Dsm Ip Assets Bv | Genes and their encoded polypeptides involved in the biosynthetic pathway of vitamin b12, vectors and host cells comprising the genes, and process for producing vitamin b12 |
| GB2409681B (en) * | 2002-09-27 | 2007-03-28 | Powderject Res Ltd | Nucleic acid constructs for gene expression |
| GB0317511D0 (en) | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
| WO2005080581A2 (en) * | 2004-02-17 | 2005-09-01 | University Of Florida Research Foundation, Inc. | Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression |
| CN109312309B (zh) | 2016-01-08 | 2024-04-02 | 雷普利穆内有限公司 | 工程化的病毒 |
| GB201700350D0 (en) * | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849571A (en) * | 1990-10-10 | 1998-12-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Latency active herpes virus promoters and their use |
| JPH067174A (ja) * | 1992-03-13 | 1994-01-18 | Monsanto Co | ヘルペスウイルスプロモーターとｖｐ１６トランスアクチベータを用いる組換え蛋白の産生 |
-
1997
- 1997-01-10 GB GBGB9700411.3A patent/GB9700411D0/en active Pending
-
1998
- 1998-01-12 DK DK98900570T patent/DK1021553T3/da active
- 1998-01-12 KR KR10-1999-7006256A patent/KR100507399B1/ko not_active Expired - Fee Related
- 1998-01-12 CN CNB988032147A patent/CN1231589C/zh not_active Expired - Fee Related
- 1998-01-12 WO PCT/GB1998/000074 patent/WO1998030707A2/en not_active Ceased
- 1998-01-12 CA CA002278326A patent/CA2278326A1/en not_active Abandoned
- 1998-01-12 BR BR9806866-0A patent/BR9806866A/pt not_active Application Discontinuation
- 1998-01-12 DE DE69824027T patent/DE69824027T2/de not_active Expired - Lifetime
- 1998-01-12 PT PT98900570T patent/PT1021553E/pt unknown
- 1998-01-12 JP JP53066398A patent/JP2001508294A/ja not_active Ceased
- 1998-01-12 AU AU55669/98A patent/AU749064B2/en not_active Ceased
- 1998-01-12 EP EP98900570A patent/EP1021553B1/en not_active Expired - Lifetime
- 1998-01-12 EP EP04008341A patent/EP1441033A3/en not_active Withdrawn
- 1998-01-12 AT AT98900570T patent/ATE267263T1/de not_active IP Right Cessation
- 1998-01-12 ES ES98900570T patent/ES2221980T3/es not_active Expired - Lifetime
- 1998-01-12 IL IL13087698A patent/IL130876A0/xx not_active IP Right Cessation
-
1999
- 1999-07-09 IL IL130876A patent/IL130876A/en unknown
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10328136B2 (en) | 2010-04-16 | 2019-06-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors |
| US11419926B2 (en) | 2010-04-16 | 2022-08-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors |
| JP2020156483A (ja) * | 2013-07-17 | 2020-10-01 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞 |
| JP2016525349A (ja) * | 2013-07-17 | 2016-08-25 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞 |
| JP7541370B2 (ja) | 2013-07-17 | 2024-08-28 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞 |
| US10174341B2 (en) | 2013-07-17 | 2019-01-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production |
| JP2022119953A (ja) * | 2013-07-17 | 2022-08-17 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞 |
| JP7086409B2 (ja) | 2013-07-17 | 2022-06-20 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞 |
| US10172893B2 (en) | 2013-10-28 | 2019-01-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Oncolytic HSV vector |
| US10576115B2 (en) | 2013-10-28 | 2020-03-03 | University of Pittsburgh—of the Commonwealth System of Higher Education | Oncolytic HSV vector |
| US10188686B2 (en) | 2013-10-28 | 2019-01-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | Oncolytic HSV vector |
| US11883448B2 (en) | 2013-10-28 | 2024-01-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Oncolytic HSV vector |
| US10201575B2 (en) | 2013-10-28 | 2019-02-12 | University of Pittsburgh—of the Commonwealth System of Higher Education | Oncolytic HSV vector |
| US10391132B2 (en) | 2016-01-27 | 2019-08-27 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| US11452750B2 (en) | 2016-01-27 | 2022-09-27 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| US11612625B2 (en) | 2017-07-26 | 2023-03-28 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| US12208126B2 (en) | 2017-07-26 | 2025-01-28 | Virogin Biotech Canada Ltd. | Oncolytic viral vectors and uses thereof |
| JP2022534119A (ja) * | 2019-05-30 | 2022-07-27 | ソリッド・バイオサイエンシーズ・インコーポレーテッド | 組換えヘルペスウイルスベクター |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69824027D1 (de) | 2004-06-24 |
| AU5566998A (en) | 1998-08-03 |
| ES2221980T3 (es) | 2005-01-16 |
| DE69824027T2 (de) | 2004-10-28 |
| AU749064B2 (en) | 2002-06-20 |
| IL130876A0 (en) | 2001-01-28 |
| CA2278326A1 (en) | 1998-07-16 |
| KR100507399B1 (ko) | 2005-08-10 |
| EP1441033A2 (en) | 2004-07-28 |
| EP1021553B1 (en) | 2004-05-19 |
| ATE267263T1 (de) | 2004-06-15 |
| WO1998030707A3 (en) | 1998-09-11 |
| IL130876A (en) | 2006-08-20 |
| EP1021553A2 (en) | 2000-07-26 |
| EP1441033A3 (en) | 2004-12-01 |
| KR20000070037A (ko) | 2000-11-25 |
| CN1250480A (zh) | 2000-04-12 |
| GB9700411D0 (en) | 1997-02-26 |
| CN1231589C (zh) | 2005-12-14 |
| BR9806866A (pt) | 2000-04-18 |
| PT1021553E (pt) | 2004-09-30 |
| DK1021553T3 (da) | 2004-09-27 |
| WO1998030707A2 (en) | 1998-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU749017B2 (en) | Mutant herpes simplex viruses and uses thereof | |
| JP2001508294A (ja) | 真核細胞遺伝子発現カセットおよびその使用 | |
| AU726645B2 (en) | HSV strain lacking functional ICP27 and ICP34.5 Genes | |
| US20040063094A1 (en) | Mutant herpes simplex viruses and uses thereof | |
| JP2000501933A (ja) | ウイルスベクター | |
| JP2003518080A (ja) | 遺伝子治療用の複製不能ヘルペスウイルス | |
| JP2003508055A (ja) | ヘルペスγ３４．５遺伝子発現の細胞特異的および／または腫瘍特異的プロモーター再標的化 | |
| AU756892B2 (en) | Mutant herpes simplex viruses and uses thereof | |
| US20030219409A1 (en) | Eukaryotic gene expression cassette and uses thereof | |
| JP2002526039A (ja) | 突然変異ヘルペスウイルスを増殖するための細胞系 | |
| MXPA99006454A (en) | Eukaryotic gene expression cassette and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041109 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041109 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080805 |
|
| A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20081229 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090224 |